心通醫療-B(02160.HK)於阿根廷註冊ALWIDE PLUS球囊導管
格隆匯3月7日丨心通醫療-B(02160.HK)發佈公吿,公司自主研發的Alwide Plus球囊導管已於阿根廷成功註冊。
Alwide Plus為公司Alwide球囊導管的升級二代產品,於2021年7月29日獲得中國國家藥品監督管理局的註冊批准。其主要特點包括:(i)低順應性能夠實現更準確的球囊擴張尺寸;(ii)高爆破壓力適合嚴重鈣化的病變;(iii)快速充盈╱回抽可最大限度地減少起搏時間。與第一代產品相比,Alwide Plus旨在提升爆破壓力。公司認為Alwide Plus可降低在TAVI(經導管主動脈瓣植入)手術中進行瓣膜成形術的挑戰性。
公司認為,Alwide Plus於阿根廷的註冊標誌着公司又向公司的國際發展藍圖邁出了堅實的一步,並將促進公司的TAVI產品VitaFlow及VitaFlow Liberty經導管主動脈瓣植入系統在阿根廷的推廣和應用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.